Search
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalWe are collaborating with the National Cancer Institute (NCI) on three clinical trials of SGN-30 in combination with chemotherapy for the treatment of relapsed Hodgkin lymphoma, front-line ALCL and pediatric … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.
Uric acid
go.drugbank.com/drugs/DB08844InvestigationalIn one country, Spain, uric acid is an investigational drug in a phase 3 trial studying its effects as an adjunct to alteplase in acute ischemic stroke. … Normally a small amount of uric acid is present in the body, but when there is an excess amount in the blood, called hyperuricemia, this can lead to gout and formation of kidney stones.
Categories: Compounds used in a research, industrial, or household settingIsocarboxazid
go.drugbank.com/drugs/DB01247ApprovedIt is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. … [T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Dihydrocodeine
go.drugbank.com/drugs/DB01551ApprovedIllicitIt was marketed in 1911. … It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis
Products: PARACODIN N, PARACODIN N TROPFENNedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigational[A261685] Nedosiran was approved by the FDA on October 2<sup>nd</sup>, 2023, under the brand name RIVFLOZA to lower urinary oxalate levels in children 9 years of age and older and adults with primary … Nedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate.
Tizanidine
go.drugbank.com/drugs/DB00697ApprovedInvestigationalInitially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons … It may also be caused by musculoskeletal injury [A177583]. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition.
Icaridin
go.drugbank.com/drugs/DB14074InvestigationalIcaridin has been commonly used as a topically-applied insect repellent in various countries but was officially licensed for use in the United States in 2001 and Canada in 2012 [L4595]. … Icaridin was synthesized by Bayer in the 1980s based on molecular modeling [L4595].
Categories: Compounds used in a research, industrial, or household settingFidaxomicin
go.drugbank.com/drugs/DB08874ApprovedInvestigationalFidaxomicin is a novel macrolide antibiotic used in the treatment of diarrhea caused by _Clostridioides_ (formerly _Clostridium_) _difficile_ in adult and pediatric patients over the age of 6 months. … [A190501] Because fidaxomicin contains an 18-membered lactone ring in its structure, it is referred to as a macrocyclic lactone antibiotic drug.
Voglibose
go.drugbank.com/drugs/DB04878InvestigationalIt is made in India by Ranbaxy Labs and sold under the trade name Volix. … Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.
Categories: Drugs Used in DiabetesLevobetaxolol
go.drugbank.com/drugs/DB09351ApprovedLevobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. … It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.